Suppr超能文献

VYC-12 注射凝胶治疗面部细纹后皮肤满意度的改善:来自前瞻性研究的患者报告结果。

Improvements in satisfaction with skin after treatment of facial fine lines with VYC-12 injectable gel: Patient-reported outcomes from a prospective study.

机构信息

SkinConcept, Munich, Germany.

La Jouvence, Neuchâtel, Switzerland.

出版信息

J Cosmet Dermatol. 2020 May;19(5):1065-1070. doi: 10.1111/jocd.13129. Epub 2019 Oct 17.

Abstract

BACKGROUND

VYC-12, a hyaluronic acid injectable gel, is designed to treat fine lines and provides improvements in other skin quality attributes. A prospective study demonstrated the safety and effectiveness of VYC-12 for the improvement of fine lines as measured by changes in skin texture.

AIMS

To evaluate patient-reported outcomes in subjects treated intradermally with VYC-12 in the cheeks, forehead, and neck (optional) in the prospective study.

METHODS

Subjects received an initial treatment of VYC-12 (N = 131), with a touch-up treatment, if deemed necessary, offered 30 days later, and optional repeat treatment 9 months after initial or touch-up treatment. Subjects completed the FACE-Q Satisfaction With Skin scale and assessed willingness to recommend treatment to a friend at baseline, months 1, 4, 6, and 9, and month 1 after repeat treatment. Subjects also evaluated their return to normal daily social activities.

RESULTS

Satisfaction with skin improved from baseline in 90.8% of subjects at month 1, 88.4% at month 4, 83.6% at month 6, 76.4% at month 9, and 91.9% at month 1 after repeat treatment (P < .001, all time points). At least 94% of subjects returned to normal daily social activities one day after treatment (initial, touch-up, or repeat). More than 80% of subjects said they would recommend treatment to a friend at all time points through month 9 (97% at month 1 after repeat treatment).

CONCLUSION

Treatment with VYC-12 significantly improved satisfaction with skin in the majority of subjects, with most subjects returning to normal activities 1 day after treatment.

摘要

背景

VYC-12 是一种透明质酸注射凝胶,旨在治疗细纹,并改善其他皮肤质量属性。一项前瞻性研究表明,VYC-12 治疗细纹的安全性和有效性,可通过皮肤质地的变化来衡量。

目的

评估在面颊、前额和颈部(可选)接受 VYC-12 真皮内注射的受试者的患者报告结果,这是一项前瞻性研究。

方法

受试者接受了初始 VYC-12 治疗(N=131),如果需要,在 30 天后进行补充治疗,并在初始或补充治疗后 9 个月进行可选的重复治疗。受试者在基线、第 1、4、6 和 9 个月以及重复治疗后 1 个月完成了 FACE-Q 皮肤满意度量表,并评估了他们向朋友推荐治疗的意愿。受试者还评估了他们恢复正常日常社交活动的情况。

结果

90.8%的受试者在第 1 个月、88.4%在第 4 个月、83.6%在第 6 个月、76.4%在第 9 个月和第 1 个月在重复治疗后(P<.001,所有时间点)对皮肤满意度提高。治疗后一天内,超过 94%的受试者恢复正常日常社交活动(初始、补充或重复)。超过 80%的受试者在所有时间点(重复治疗后第 1 个月为 97%)表示愿意向朋友推荐治疗。

结论

VYC-12 治疗显著改善了大多数受试者对皮肤的满意度,大多数受试者在治疗后 1 天即可恢复正常活动。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验